Indian Journal of Pharmacy Practice logo
Submit
Indian Journal of Pharmacy PracticeACADEMIC PUBLISHING
Article

Study of FE (III) Hydroxide Polymaltose Complex to Correct Anemia in Cancer Patients

1, 1

  1. 1A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Mota Bazar, Vallabh Vidyanagar- 388120, Anand, Gujarat, INDIA.

CORRESPONDENCE

Pallavi H.S

A. R. College of Pharmacy and G. H. Patel Institute of Pharmacy, Mota Bazar, Vallabh Vidyanagar- 388120, Anand, Gujarat, INDIA.

pallavishethia@gmail.com

Received: 19-09-2012; Accepted: 25-11-2012.

Volume 5, Issue 4 · pp. 56-60 · 2012 · DOI:

ABSTRACT

Introduction: Anemia of cancer is characterized by ineffective erythropoiesis, which is due to a number of factors. One of the most important among these is abnormal iron metabolism. There is also 'functional failure' due to retention of iron in macrophages. Hence iron supplementation 2+ forms an important part for the treatment of anemia in cancer patients. Oral iron supplements, usually in the form of ferrous (Fe ) salts, are toxic to the gastrointestinal mucosa, leading to intolerance, resulting in poor compliance and failure of treatment. The sugar derivative maltose strongly 3+ chelates iron, and stabilizes in the less toxic ferric (Fe ) form. This chelated form of iron shows high bioavailability which eliminates the need for frequent dosing and therefore improves compliance.Materials and Method: This was a prospective, single centred, open label, nonrandomised study involving 20 patients of whom 17 completed the study. The patients were treated with ferric hydroxide polymaltose complex syrup (50mg/5ml) for 8 weeks.Results: At the end of 8 weeks, there was a significant increase in haemoglobin of the patients (from 9.41±1.24 to 10.92±0.91 g/dL, mean±s.d. P< 0.0001, paired t-test, t = 7.065, df = 16, confidence interval - 0.05.). Out of 17, 7 patients i.e. 41.18% showed a ≥ 2 g/dl rise in hemoglobin during or at the end of the treatment. Mean time required to achieve this rise in hemoglobin is found to be 7 weeks.Conclusion: The results demonstrate that Fe (III) hydroxide polymaltose complex is effective in improving hemoglobin levels in anemic cancer patients.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    H.S, P., & N.S, N. (2012). Study of FE (III) Hydroxide Polymaltose Complex to Correct Anemia in Cancer Patients. Indian Journal of Pharmacy Practice, 5(4), 56-60.

    Copyright and licence

    © 2012 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CC BY 4.0